CSF3 and thromboangiitis obliterans: Horie et al. performed a randomized, large-scale clinical trial of G-CSF mobilized autologous PBMNC transplantation revealed that cell therapy was feasible and tolerable in patients with both mild and severe peripheral artery disease (PAD); however, this study only included nine patients with TAO followed by 12 months (10).